James B. Dale

9.4k total citations · 1 hit paper
152 papers, 7.0k citations indexed

About

James B. Dale is a scholar working on Public Health, Environmental and Occupational Health, Infectious Diseases and Epidemiology. According to data from OpenAlex, James B. Dale has authored 152 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Public Health, Environmental and Occupational Health, 92 papers in Infectious Diseases and 35 papers in Epidemiology. Recurrent topics in James B. Dale's work include Streptococcal Infections and Treatments (131 papers), Antimicrobial Resistance in Staphylococcus (87 papers) and Neonatal and Maternal Infections (67 papers). James B. Dale is often cited by papers focused on Streptococcal Infections and Treatments (131 papers), Antimicrobial Resistance in Staphylococcus (87 papers) and Neonatal and Maternal Infections (67 papers). James B. Dale collaborates with scholars based in United States, Australia and South Africa. James B. Dale's co-authors include E H Beachey, Harry S. Courtney, David L. Hasty, Michael S. Bronze, Edna Y. Chiang, Thomas A. Penfound, Jerome M. Seyer, Bernard Beall, Mark A. Reddish and W A Simpson and has published in prestigious journals such as Nature, Cell and JAMA.

In The Last Decade

James B. Dale

151 papers receiving 6.7k citations

Hit Papers

Blocking Neuronal Signaling to Immune Cells Treats Strept... 2018 2026 2020 2023 2018 100 200 300

Peers

James B. Dale
Malak Kotb United States
P. Patrick Cleary United States
Michael R. Wessels United States
Shiranee Sriskandan United Kingdom
John D. Fraser New Zealand
Kenneth L. Tyler United States
Debra E. Bessen United States
Elía M. Ayoub United States
James B. Dale
Citations per year, relative to James B. Dale James B. Dale (= 1×) peers Madeleine W. Cunningham

Countries citing papers authored by James B. Dale

Since Specialization
Citations

This map shows the geographic impact of James B. Dale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James B. Dale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James B. Dale more than expected).

Fields of papers citing papers by James B. Dale

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James B. Dale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James B. Dale. The network helps show where James B. Dale may publish in the future.

Co-authorship network of co-authors of James B. Dale

This figure shows the co-authorship network connecting the top 25 collaborators of James B. Dale. A scholar is included among the top collaborators of James B. Dale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James B. Dale. James B. Dale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Penfound, Thomas A., et al.. (2024). Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine. Vaccine. 42(22). 126205–126205. 5 indexed citations
2.
Dale, James B., et al.. (2023). Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine. Vaccine. 41(40). 5841–5847. 2 indexed citations
3.
Asturias, Edwin J., Jean‐Louis Excler, James Ackland, et al.. (2023). Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring. Clinical Infectious Diseases. 77(6). 917–924. 8 indexed citations
4.
Botteaux, Anne, et al.. (2021). Design of Broadly Cross-Reactive M Protein–Based Group A Streptococcal Vaccines. The Journal of Immunology. 207(4). 1138–1149. 8 indexed citations
5.
Salie, Muneeb, et al.. (2021). Utility of Human Immune Responses to GAS Antigens as a Diagnostic Indicator for ARF: A Systematic Review. Frontiers in Cardiovascular Medicine. 8. 691646–691646. 1 indexed citations
8.
Hanson, Mary, James B. Dale, Rodney K. Tweten, et al.. (2020). Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection. PLoS ONE. 15(6). e0235139–e0235139. 7 indexed citations
9.
Wozniak, Aniela, Patricia García, James B. Dale, et al.. (2018). Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M‐protein antigens derived from Group A Streptococcus. Microbiology and Immunology. 62(6). 395–404. 7 indexed citations
10.
Engel, Mark E., Andrew Whitelaw, Alemseged Abdissa, et al.. (2016). Rationale and design of the African group A streptococcal infection registry: the AFRO Strep study. BMJ Open. 6(2). e010248–e010248. 11 indexed citations
11.
Courtney, Harry S., Itzhak Ofek, Thomas A. Penfound, et al.. (2009). Correction: Relationship between Expression of the Family of M Proteins and Lipoteichoic Acid to Hydrophobicity and Biofilm Formation in Streptococcus pyogenes. PLoS ONE. 4(1). 5 indexed citations
12.
Dale, James B.. (2007). Current Status of Group A Streptococcal Vaccine Development. Advances in experimental medicine and biology. 609. 53–63. 42 indexed citations
13.
Shulman, Stanford T., Gene H. Stollerman, Bernard Beall, James B. Dale, & Robert R. Tanz. (2006). Temporal Changes in Streptococcal M Protein Types and the Near-Disappearance of Acute Rheumatic Fever in the United States. Clinical Infectious Diseases. 42(4). 441–447. 75 indexed citations
14.
Courtney, Harry S., Christina von Hunolstein, James B. Dale, et al.. (1992). Lipoteichoic acid and M protein: dual adhesins of group A streptococci. Microbial Pathogenesis. 12(3). 199–208. 63 indexed citations
15.
Bronze, Michael S., D. S. McKinsey, E H Beachey, & James B. Dale. (1988). Protective immunity evoked by locally administered group A streptococcal vaccines in mice.. The Journal of Immunology. 141(8). 2767–2770. 25 indexed citations
16.
Bronze, Michael S., E H Beachey, & James B. Dale. (1988). Protective and heart-crossreactive epitopes located within the NH2 terminus of type 19 streptococcal M protein.. The Journal of Experimental Medicine. 167(6). 1849–1859. 33 indexed citations
17.
Beachey, E H, Jerome M. Seyer, & James B. Dale. (1987). Protective immunogenicity and T lymphocyte specificity of a trivalent hybrid peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandem.. The Journal of Experimental Medicine. 166(3). 647–656. 39 indexed citations
18.
Dale, James B. & E H Beachey. (1987). Human cytotoxic T lymphocytes evoked by group A streptococcal M proteins.. The Journal of Experimental Medicine. 166(6). 1825–1835. 27 indexed citations
19.
Dale, James B. & E H Beachey. (1986). Sequence of myosin-crossreactive epitopes of streptococcal M protein.. The Journal of Experimental Medicine. 164(5). 1785–1790. 91 indexed citations
20.
Dale, James B. & E H Beachey. (1986). Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein.. The Journal of Experimental Medicine. 163(5). 1191–1202. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026